MoonLake Immunotherapeutics Past Earnings Performance
Past criteria checks 0/6
MoonLake Immunotherapeutics has been growing earnings at an average annual rate of 27.9%, while the Biotechs industry saw earnings growing at 13.4% annually.
Key information
27.9%
Earnings growth rate
56.9%
EPS growth rate
| Biotechs Industry Growth | 12.9% |
| Revenue growth rate | n/a |
| Return on equity | -8.6% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How MoonLake Immunotherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -36 | 22 | 32 |
| 30 Sep 23 | 0 | -46 | 21 | 35 |
| 30 Jun 23 | 0 | -46 | 21 | 37 |
| 31 Mar 23 | 0 | -43 | 23 | 39 |
| 31 Dec 22 | 0 | -50 | 23 | 42 |
| 30 Sep 22 | 0 | -58 | 31 | 38 |
| 30 Jun 22 | 0 | -54 | 30 | 4 |
Quality Earnings: MLTX N is currently unprofitable.
Growing Profit Margin: MLTX N is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if MLTX N's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare MLTX N's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MLTX N is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: MLTX N has a negative Return on Equity (-8.58%), as it is currently unprofitable.